Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 137Cisplatin 75Cetuximab 51Carboplatin 49Paclitaxel 39Nivolumab 38Radiotherapy 37Docetaxel 34Radiotherapy, Intensity-Modulated 30Magnetic Resonance Spectroscopy 25Specimen Handling 20Fluorouracil 20Platinum 141,2-diaminocyclohexaneplatinum II citrate 13Taxes 12cemiplimab 11Radiation 11Ipilimumab 11atezolizumab 10Surgical Procedures, Operative 10Drug Therapy 10Biopsy 9durvalumab 8Radiosurgery 8130-nm albumin-bound paclitaxel 8tislelizumab 7Standard of Care 7Chemoradiotherapy 7Albumin-Bound Paclitaxel 7Immune Checkpoint Inhibitors 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Receptors, Vascular Endothelial Growth Factor × 1 year × Clear all
NCT04777994 2026-06-04

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Calico Life Sciences LLC

Phase 1 Recruiting
248 enrolled
GenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡